Fundamental investigations have demonstrated that minocycline inhibits caspase-1 activity in mice suffering from traumatic brain injury (TBI) (227); reduces the expression of caspase-1 to alleviate stress-induced depression in mice (228); acts as a caspase-1 inhibitor to delay the death of mice with Huntington’s disease (229); reduces caspase-1 activity in the retina of diabetic mice (230) and suppresses caspase-1 activation in mice with acute lung injury to reduce inflammation (231). Here, CASP1 is linked to major depressive disorder.